Japan’s Eisai announced the availability in the U.S. of its Fycompa (perampanel) oral suspension for patients who have problems swallowing tablets. The oral suspension, which got FDA approval in April, is a bioequivalent interchangeable alternative to Fycompa tablets.
Fycompa is used as an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures, and primary generalized tonic-clonic seizures in patients with epilepsy in patients 12 years or older, the company said.
The new oral suspension formulation was developed to provide a new option for patients who have difficulty swallowing tablets.
Epilepsy affects approximately 2.9 million people in the U.S. Epilepsy is broadly categorized by seizure type, with partial-onset seizures accounting for approximately 60 percent of epilepsy cases and generalized seizures accounting for approximately 40 percent.
In April, Eisai announced it contracted with Russia's PharmStandard to manufacture three of its meds, oncology drugs Halaven and Lenvima and epilepsy med Fycompa. Eisai said the deal calls for PharmStandard to manufacture the cancer meds at its facilities in Ufa, and the seizure product at its plant in Kursk.
- here’s the release